Nixon Ronald T

SEC source: 0001493152-26-027590 · ownership.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,196

F1 · shares: Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest on the earlier of (i) the date of the 2027 annual shareholder meeting or (ii) June 04, 2027, provided that the reporting person is providing certain services to the Issuer through such date.

SEC source: 0001493152-25-008520 · ownership.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,042

F1 · shares: Represents shares of restricted stock granted to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest in three equal installments, with one-third of the shares vesting on February 25, 2026, 2027 and 2028, respectively.

SEC source: 0001493152-24-023960 · ownership.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,508

F1 · shares: Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Company") to the reporting person pursuant to the Sanara MedTech Inc. 2014 Omnibus Long-Term Incentive Plan, as amended and restated. The shares of restricted stock will vest on June 12, 2025, provided that the reporting person is providing certain services to the Company through such date.

SEC source: 0001493152-23-020179 · ownership.xml · nonDerivative · entry 2

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,696

F2 · shares: Represents shares of restricted stock granted by the Company to the reporting person pursuant to the Sanara MedTech Inc. 2014 LTIP. The shares of restricted stock will vest on the earlier of (i) the date of the 2024 annual shareholder meeting or (ii) June 1, 2024, provided that the reporting person is providing certain services to the Company on such date.

SEC source: 0001493152-23-020179 · ownership.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,888

F1 · shares: Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Company") to the reporting person pursuant to the Sanara MedTech Inc. 2014 Omnibus Long-Term Incentive Plan, as amended and restated (the "2014 LTIP"). The shares of restricted stock vested in full on the date of grant.

SEC source: 0001303313-23-000046 · wf-form4_167710185595331.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: Each share of issuer common stock was cancelled pursuant to the merger agreement between the issuer and UnitedHealth Group Incorporated in exchange for a cash payment equal to $170.00.

SEC source: 0001493152-22-018949 · ownership.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,279

F1 · shares: Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Company") to the reporting person pursuant to the Sanara MedTech Inc. 2014 Omnibus Long-Term Incentive Plan, as amended and restated. The shares of restricted stock will vest on June 10, 2023, provided that the reporting person is providing certain services to the Company on such date.

SEC source: 0001303313-22-000024 · wf-form4_164634397352390.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,100

F1 · kind: Restricted stock granted pursuant to the 2005 Non-Employee Director Compensation Plan, which vests on the first anniversary of the grant date.

SEC source: 0001493152-22-004120 · ownership.xml · nonDerivative · entry 3

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,166

F2 · shares: Represents shares of restricted stock granted to the reporting person pursuant to the Sanara MedTech Inc. 2014 Omnibus Long-Term Incentive Plan, as amended and restated. The shares of restricted stock will vest on the date of the Company's 2022 annual meeting of shareholders; provided that the reporting person is providing services to the Company until such date.

SEC source: 0001493152-22-004120 · ownership.xml · nonDerivative · entry 2

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,254

F1 · shares: Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Company") to the reporting person pursuant to the Sanara MedTech Inc. 2014 Omnibus Long-Term Incentive Plan, as amended and restated. All of the shares of restricted stock vested on February 9, 2022.

SEC source: 0001493152-22-004120 · ownership.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,429

F1 · shares: Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Company") to the reporting person pursuant to the Sanara MedTech Inc. 2014 Omnibus Long-Term Incentive Plan, as amended and restated. All of the shares of restricted stock vested on February 9, 2022.

SEC source: 0001303313-21-000050 · wf-form4_162223320292559.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,000

F1 · price: The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The price reflects the weighted average sale price, and the range of prices for such transaction is $201.58 to $201.95. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001303313-21-000035 · wf-form4_161480923792469.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,000

F1 · kind: Restricted stock granted pursuant to the 2005 Non-Employee Director Compensation Plan, which vests on the first anniversary of the grant date.

SEC source: 0001303313-20-000034 · wf-form4_158318853287173.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,200

SEC source: 0000897423-20-000051 · edgar.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,229

SEC source: 0000897423-20-000029 · edgar.xml · nonDerivative · entry 4

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F5 · kind: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 7,229 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

F5 · price: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 7,229 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

SEC source: 0000897423-20-000029 · edgar.xml · derivative · entry 6

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 179,101 shares

Expires 2021-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The 5% Convertible Promissory Note in the principal amount of $1,500,000 was convertible into Common Stock at any time prior to maturity at an initial conversion price of $0.09 per share. As a result a 1-for-100 reverse stock split of the Common Stock on May 10, 2019, the conversion price was automatically adjusted to $9.00 per share in accordance with the terms of the Promissory Note. The terms of the Promissory Note also provided for the right of conversion of any accrued and unpaid interest. The amount of $111,911 in accrued interest was also converted into 12,434 shares of Common Stock at $9.00 per share.

F3 · price: The 5% Convertible Promissory Note in the principal amount of $1,500,000 was convertible into Common Stock at any time prior to maturity at an initial conversion price of $0.09 per share. As a result a 1-for-100 reverse stock split of the Common Stock on May 10, 2019, the conversion price was automatically adjusted to $9.00 per share in accordance with the terms of the Promissory Note. The terms of the Promissory Note also provided for the right of conversion of any accrued and unpaid interest. The amount of $111,911 in accrued interest was also converted into 12,434 shares of Common Stock at $9.00 per share.

F3 · ownership.nature: The 5% Convertible Promissory Note in the principal amount of $1,500,000 was convertible into Common Stock at any time prior to maturity at an initial conversion price of $0.09 per share. As a result a 1-for-100 reverse stock split of the Common Stock on May 10, 2019, the conversion price was automatically adjusted to $9.00 per share in accordance with the terms of the Promissory Note. The terms of the Promissory Note also provided for the right of conversion of any accrued and unpaid interest. The amount of $111,911 in accrued interest was also converted into 12,434 shares of Common Stock at $9.00 per share.

SEC source: 0000897423-20-000029 · edgar.xml · derivative · entry 5

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,273,630 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series F Convertible Preferred Stock was convertible into Common Stock at any time on a 2-for-1 basis and had no expiration date. When originally issued the conversion rate was 200-for-1, but on May 10, 2019, as a result of a 1-for-100 reverse stock split of the Common Stock, the conversion rate was automatically adjusted to a conversion rate of 2-for-1 in accordance with the terms of the Series F Convertible Preferred Stock.

F1 · price: The Series F Convertible Preferred Stock was convertible into Common Stock at any time on a 2-for-1 basis and had no expiration date. When originally issued the conversion rate was 200-for-1, but on May 10, 2019, as a result of a 1-for-100 reverse stock split of the Common Stock, the conversion rate was automatically adjusted to a conversion rate of 2-for-1 in accordance with the terms of the Series F Convertible Preferred Stock.

F1 · derivative.exercise_date: The Series F Convertible Preferred Stock was convertible into Common Stock at any time on a 2-for-1 basis and had no expiration date. When originally issued the conversion rate was 200-for-1, but on May 10, 2019, as a result of a 1-for-100 reverse stock split of the Common Stock, the conversion rate was automatically adjusted to a conversion rate of 2-for-1 in accordance with the terms of the Series F Convertible Preferred Stock.

F1 · derivative.expiration_date: The Series F Convertible Preferred Stock was convertible into Common Stock at any time on a 2-for-1 basis and had no expiration date. When originally issued the conversion rate was 200-for-1, but on May 10, 2019, as a result of a 1-for-100 reverse stock split of the Common Stock, the conversion rate was automatically adjusted to a conversion rate of 2-for-1 in accordance with the terms of the Series F Convertible Preferred Stock.

F1 · ownership.nature: The Series F Convertible Preferred Stock was convertible into Common Stock at any time on a 2-for-1 basis and had no expiration date. When originally issued the conversion rate was 200-for-1, but on May 10, 2019, as a result of a 1-for-100 reverse stock split of the Common Stock, the conversion rate was automatically adjusted to a conversion rate of 2-for-1 in accordance with the terms of the Series F Convertible Preferred Stock.

SEC source: 0000897423-20-000029 · edgar.xml · nonDerivative · entry 2

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,452,731

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The 5% Convertible Promissory Note in the principal amount of $1,500,000 was convertible into Common Stock at any time prior to maturity at an initial conversion price of $0.09 per share. As a result a 1-for-100 reverse stock split of the Common Stock on May 10, 2019, the conversion price was automatically adjusted to $9.00 per share in accordance with the terms of the Promissory Note. The terms of the Promissory Note also provided for the right of conversion of any accrued and unpaid interest. The amount of $111,911 in accrued interest was also converted into 12,434 shares of Common Stock at $9.00 per share.

F2 · ownership.nature: Reflects shares of Common Stock owned of record by CGI Cellerate RX, LLC, which is a wholly owned subsidiary of Catalyst Rochal, LLC. Mr. Nixon is a manager of Catalyst Rochal, LLC. By virtue of these relationships, Mr. Nixon, Catalyst Rochal, LLC and CGI Cellerate RX, LLC may be deemed to share voting and dispositive control over the Common Stock. Mr. Nixon and Catalyst Rochal, LLC disclaim beneficial ownership of any Common Stock held or beneficially owned by CGI Cellerate RX, LLC, except to the extent of each of their pecuniary interests therein.

F3 · ownership.nature: The 5% Convertible Promissory Note in the principal amount of $1,500,000 was convertible into Common Stock at any time prior to maturity at an initial conversion price of $0.09 per share. As a result a 1-for-100 reverse stock split of the Common Stock on May 10, 2019, the conversion price was automatically adjusted to $9.00 per share in accordance with the terms of the Promissory Note. The terms of the Promissory Note also provided for the right of conversion of any accrued and unpaid interest. The amount of $111,911 in accrued interest was also converted into 12,434 shares of Common Stock at $9.00 per share.

SEC source: 0000897423-20-000029 · edgar.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,273,630

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series F Convertible Preferred Stock was convertible into Common Stock at any time on a 2-for-1 basis and had no expiration date. When originally issued the conversion rate was 200-for-1, but on May 10, 2019, as a result of a 1-for-100 reverse stock split of the Common Stock, the conversion rate was automatically adjusted to a conversion rate of 2-for-1 in accordance with the terms of the Series F Convertible Preferred Stock.

F1 · ownership.nature: The Series F Convertible Preferred Stock was convertible into Common Stock at any time on a 2-for-1 basis and had no expiration date. When originally issued the conversion rate was 200-for-1, but on May 10, 2019, as a result of a 1-for-100 reverse stock split of the Common Stock, the conversion rate was automatically adjusted to a conversion rate of 2-for-1 in accordance with the terms of the Series F Convertible Preferred Stock.

F2 · ownership.nature: Reflects shares of Common Stock owned of record by CGI Cellerate RX, LLC, which is a wholly owned subsidiary of Catalyst Rochal, LLC. Mr. Nixon is a manager of Catalyst Rochal, LLC. By virtue of these relationships, Mr. Nixon, Catalyst Rochal, LLC and CGI Cellerate RX, LLC may be deemed to share voting and dispositive control over the Common Stock. Mr. Nixon and Catalyst Rochal, LLC disclaim beneficial ownership of any Common Stock held or beneficially owned by CGI Cellerate RX, LLC, except to the extent of each of their pecuniary interests therein.

SEC source: 0000897423-20-000013 · edgar.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,229

SEC source: 0000897423-19-000065 · edgar.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 963,856

F1 · ownership.nature: Reflects shares of Common Stock owned of record by FA Sanara, LLC ("FA Sanara"). FA Sanara is managed by Family Alignment, LLC ("Family"), which is managed by Catalyst Group, Inc.("Catalyst"). Mr. Nixon is controlling shareholder and President of Catalyst. Brad Gurasich has an economic interest in FA Sanara and is a manager of FA Sanara and Family. Mr. Nixon, Mr. Gurasich, Catalyst, Family and FA Sanara may be deemed to share voting and dispositive control over the Common Stock. Mr. Nixon, Mr. Gurasich, Catalyst and Family disclaim beneficial ownership of any Common Stock held or beneficially owned by FA Sanara, except to the extent of each of their pecuniary interests therein.

SEC source: 0001303313-19-000059 · wf-form4_155855920996637.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,100

F1 · price: The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The price reflects the weighted average sale price, and the range of prices for such transaction is $116.73 to $118.07. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001303313-19-000031 · wf-form4_155173566854862.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,100

F1 · kind: Restricted stock granted pursuant to the 2005 Non-Employee Director Compensation Plan, which vests on the first anniversary of the grant date.

SEC source: 0001303313-18-000020 · wf-form4_152028661374668.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,900

F1 · kind: Restricted stock granted pursuant to the 2005 Non-Employee Director Compensation Plan, which vests on the first anniversary of the grant date.

SEC source: 0001303313-17-000023 · wf-form4_148857875185460.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,200

F1 · kind: Restricted stock granted pursuant to the 2005 Non-Employee Director Compensation Plan, which vests on the first anniversary of the grant date.